According to our new research study on “Low Molecular Weight Heparin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type, Packaging, Application, and End Use,” the market is expected to grow from US$ 3,658.27 million in 2021 to US$ 5,733.96 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028. The report highlights trends existing in the market, and drivers and hindrances pertaining to the market growth. Enoxaparin is a low molecular weight heparin (LMWH) produced from heparin that was licenced for medicinal use in 1993. It is approved for the treatment and prophylaxis of acute coronary syndromes (ACS), deep vein thrombosis (DVT), pulmonary embolism (PE), venous thromboembolism (VTE) in a range of situations, percutaneous coronary intervention (PCI), and periprocedural anticoagulation. This exercise will review the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of enoxaparin, which would be beneficial for the members of the interprofessional team treating patients with illnesses for which this medication is appropriate.
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis – https://www.theinsightpartners.com/sample/TIPRE00026174/
The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. However, the ambulatory surgical centers segment is anticipated to register the highest CAGR in the market during the forecast period.
Aspen Holdings; Changzhou Qianhong Bio-Pharma; Leopharma A/S; Teva Pharmaceutical Industries Ltd.; B. Braun Medical, Inc.; Pfizer, Inc.; Sanofi; Dr. Reddy's Laboratories Limited; Abbott; and Novartis AG are a few leading companies operating in the low molecular weight heparin market. The companies adopt inorganic and organic growth strategies to expand their footprints and product portfolio worldwide to meet the rising demands for low molecular weight heparin. In July 2020, Novartis launched first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19.
Geographically, the low molecular weight heparin market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).
Click here to avail lucrative discounts on our latest reports. We offer student, enterprise, and special periodic discounts to our clientele. Please fill the inquiry form below to know more – https://www.theinsightpartners.com/discount/TIPRE00026174/
The global low molecular weight heparin market, based on product type, is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. However, the dalteparin segment is anticipated to register the highest CAGR in the market during the forecast period.
The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes. In 2021, the multi-vials segment held a larger share of the market, whereas the prefilled syringes segment is expected to register the highest CAGR during 2021–2028.
The global low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. However, the acute coronary syndrome (ACS) segment is anticipated to register the highest CAGR in the market during the forecast period.
Impact of COVID
The spread of the COVID-19 pandemic has emphasized health data sharing and interoperability under the microscope. The infection of novel coronavirus in children is mild compared to adults, and children are assigned a better prognosis. The interruptions in the supply chain and the massive demand for efficient treatments for COVID-19 have put the health research industry in Asia-Pacific in a crucial position.
Immediate delivery of our off-the-shelf reports and prebooking of upcoming studies, through flexible and convenient payment methods –
https://www.theinsightpartners.com/buy/TIPRE00026174/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense, Food & beverage, Chemical and Materials, Semiconductors etc.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
0
